Three-year efficacy and safety of LB03002, a once-weekly sustained-release Growth Hormone (GH) preparation, in prepubertal children with GH Deficiency (GHD)

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 2, 2012, Pages 400-407

  Péter, Ferenc ^a   Bidlingmaier, Martin ^b   Savoy, Conrad ^c   Ji, Hyi Jeong ^d   Saenger, Paul H ^e  

^a Buda Children's Hospital   (Hungary)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c BioPartners GmbH   (Switzerland)

^d LG Chemical Ltd   (South Korea)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; LB 03002; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADRENAL CORTEX HYPERFUNCTION; ARTICLE; BONE MATURATION; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; GROWTH HORMONE DEFICIENCY; GROWTH RATE; HUMAN; HYPOCORTISOLISM; HYPOTHYROIDISM; INJECTION SITE REACTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME;

BODY HEIGHT; CHILD; CHILD, PRESCHOOL; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; INFUSION PUMPS; MALE; PUBERTY; TREATMENT OUTCOME;

EID: 84856806928     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2234     Document Type: Article

References (25)

1. Rosenfeld RG, Bakker B 2008 Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract 14:143-154
2. Clemmons DR 2007 Long-acting forms of growth hormone-releasing hormone and growth hormone: effects in normal volunteers and adults with growth hormone deficiency. Horm Res 68(Suppl 5):178-181
3. Cook DM, Biller BM, Vance ML, Hoffman AR, Phillips LS, Ford KM, Benziger DP, Illeperuma A, Blethen SL, Attie KM, Dao LN, Reimann JD, Fielder PJ 2002 The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (Nutropin Depot) in GH-deficient adults. J Clin Endocrinol Metab 87:4508-4514 (Pubitemid 35251858)
4. Kemp SF, Fielder PJ, Attie KM, Blethen SL, Reiter EO, Ford KM, Marian M, Dao LN, Lee HJ, Saenger P 2004 Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (Nutropin Depot) in GH-deficient children. J Clin Endocrinol Metab 89:3234-3240 (Pubitemid 38951887)
5. Jostel A, Mukherjee A, Alenfall J, Smethurst L, Shalet SM 2005 A newsustained release preparation ofhumangrowth hormone and its pharmacokinetic, pharmacodynamic and safety profile. Clin Endocrinol (Oxf) 62:623-627 (Pubitemid 40646733)
6. Harris PE, Didier E, Boonen A, Kantaridis C, Weissgerber G, Abs R 2006 The pharmacokinetics, pharmacodynamics and safety of pegylated recombinant human growth hormone after single subcutaneous injection in adult male patients with growth hormone deficiency. Horm Res 65(Suppl 4):148
7. Bidlingmaier M, Kim J, Savoy C, Kim MJ, Ebrecht N, de la Motte S, Strasburger CJ 2006 Comparative pharmacokinetics and pharmacodynamics of a new sustained release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency. J Clin Endocrinol Metab 91:2926-2930 (Pubitemid 44271737)
8. Peter F, Savoy C, Ji HJ, Juhasz M, Bidlingmaier M, Saenger P 2009 Pharmacokinetic and pharmacodynamic profile of a new sustainedrelease GH formulation, LB03002, in children with GH deficiency. Eur J Endocrinol 160:349-355
9. Reiter EO, Attie KM, Moshang T Jr, Silverman BL, Kemp SF, Neuwirth RB, Ford KM, Saenger P 2001 A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency. J Clin Endocrinol Metab 86: 4700-4706 (Pubitemid 33020508)
10. Hoffman AR, Biller BM, Cook D, Baptista J, Silverman BL, Dao L, Attie KM, Fielder P, Maneatis T, Lippe B; Genentech Adult Growth Hormone Deficiency Study Group 2005 Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. J Clin Endocrinol Metab 90:6431-6440 (Pubitemid 41759296)
11. Peterkova V, Arslanoglu I, Bolshova-Zubkovskaya E, Romer T, Zdravkovic D, Kratzsch J, Ji HJ, Savoy C, Saenger P 2007 A randomized, double-blind study to assess the efficacy and safety of valtropin, a biosimilar growth hormone, in children with growth hormone deficiency. Horm Res 68:288-293 (Pubitemid 350059702)
12. Prader A, Largo RH, Molinari L, Issler C 1989 Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development. Helv Paediatr Acta Suppl 52:1-125
13. Greulich WW, Pyle SI 1959 Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Palo Alto, CA: Stanford University Press
14. Elmlinger MW, Kühnel W, Weber MM, Ranke MB 2004 Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF binding protein 3 (IGFBP-3). Clin Chem Lab Med 42:654-664 (Pubitemid 38979144)
15. Brabant G, von zur Mühlen A, Wüster C, Ranke MB, Kratzsch J, Kiess W, Ketelslegers JM, Wilhelmsen L, Hulthén L, Saller B, Mattsson A, Wilde J, Schemer R, Kann P; German KIMS Board 2003 Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 60:53-60. (Pubitemid 36928670)
16. Biller BM, Ji HJ, Ahn H, Savoy C, Siepl EC, Popovic V, Coculescu M, Roemmler J, Gavrila C, Cook DM, Strasburger CJ 2011 Effects of once weekly sustained release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency. J Clin Endocrinol Metab 96:1718-1726
17. Silverman BL, Blethen SL, Reiter EO, Attie KM, Neuwirth RB, Ford KM 2002 A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency. J Pediatr Endocrinol Metab 15(Suppl 2):715-722 (Pubitemid 34700345)
18. Touraine P, D'Souza GA, Kourides I, Abs R, Barclay P, Xie R, Pico A, Torres-Vela E, Ekman B; GH Lipoatrophy Study Group 2009 Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. Eur J Endocrinol 161:533-540
19. Behan LA, Monson JP, Agha A 2011 The interaction between growth hormone and the thyroid axis in hypopituitary patients. Clin Endocrinol (Oxf) 74:281-288
20. Smyczynska J, Hilczer M, Stawerska R, Lewinski A 2010 Thyroid function in children with growth hormone (GH) deficiency during the initial phase of GH replacement therapy: clinical implications. Thyroid Res 3:2
21. Filipsson H, Johannsson G 2009 GH replacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies. Eur J Endocrinol 161(Suppl 1):S85-S95
22. Cutfield WS, Wilton P, Bennmarker H, Albertsson-Wikland K, Chatelain P, Ranke MB, Price DA 2000 Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 355:610-613 (Pubitemid 30099467)
23. Martin DD, Schweizer R, Schönau E, Binder G, Ranke MB 2009 Growth hormone-induced increases in skeletal muscle mass alleviates the associated insulin resistance in short children born small for gestational age, but not with growth hormone deficiency. Horm Res 72:38-45
24. Child CJ, Zimmermann AG, Scott RS, Cutler Jr GB, Battelino T, Blum WF; GeNeSIS International Advisory Board 2011 Prevalence and incidence of diabetes mellitus in GH-treated children and adolexcents: analysis from the GeNeSIS observational research program. J Clin Endocrinol Metab 96:E1025-E1034
25. Saenger P, Kadilkar V, Radjuk KA, Bolshova E, Khadgawat R, El Kholy M, Peterkova V, Desai M, Mericq V, Savoy C, Ji HJ, Zadik Z, Kratzsch J, Bidlingmaier M 2010 Twelve months safety and efficacy of LB03002, a new prolonged release formulation of rhGH, as compared with daily rhGH therapy in treatment-naive children with growth failure due to insufficient secretion of endogenous growth hormone (GHD). Growth Horm IGF Res 20(Suppl 1):S37-S38